PNC-27: Dosage, Benefits & Side Effects

By Peptide Assistant Editorial Team · · · 10 sources cited

Overview

PNC-27 is a synthetic anticancer peptide consisting of an HDM-2 (MDM2) binding domain fused to a cell-penetrating peptide leader sequence. In cell and animal studies it killed cancer cells carrying HDM-2 in their membranes while sparing normal cells. It has not been tested in people, and the FDA has warned consumers against using PNC-27 products sold as cancer treatments. It represents a targeted approach to cancer-cell destruction based on exploiting the differential expression of MDM2 between cancerous and healthy tissue.

Mechanism of Action

PNC-27 contains a p53 C-terminal peptide fragment that binds to HDM-2 (human double minute 2, also called MDM2), a protein found in the membranes of many cancer cell lines but, in the lines tested, not in the membranes of normal cells. When PNC-27 binds to surface-expressed HDM-2 on cancer cells, it creates transmembrane pores that disrupt membrane integrity, leading to rapid necrotic cell death. This mechanism is selective: normal cells, which express HDM-2 only internally, are not affected. The attached cell-penetrating leader sequence is penetratin, from the Antennapedia protein, and it is required for the membrane-damaging effect: without it the peptide killed cells by apoptosis instead. Importantly, PNC-27's mechanism is independent of p53 status — it works regardless of whether the cancer cell's p53 is functional, mutated, or deleted.

PNC-27 Benefits: What the Research Shows

  • Kanovsky et al. (2001) in Proceedings of the National Academy of Sciences showed that p53 peptides joined to a penetratin sequence were cytotoxic to human cancer cell lines while having no effect on normal cells, including cord blood stem cells
  • Double-labelled PNC-27 was seen concentrating in cancer cell membranes within 30 minutes and lysing them, while untransformed breast epithelial cells remained viable (Cancer Chemotherapy and Pharmacology, 2010)
  • Studies confirmed the mechanism depends on surface expression of HDM-2 — cancer cells lacking surface HDM-2 were resistant
  • Preclinical data showed activity against pancreatic, breast, ovarian, colon and melanoma cell lines and leukemia cells; in mice, PNC-27 killed acute myeloid leukemia cells while sparing normal blood stem cells
  • Sookraj et al. (2010) showed the intact peptide, rather than a fragment, causes the membrane damage, and a 2022 study visualised pores containing PNC-27 and HDM-2 by immuno-electron microscopy, with no pores in untransformed fibroblasts

PNC-27 Dosage

  • Research use only — no established human dosing protocol
  • Preclinical doses: 50–200 mcg/mL in cell culture; in vivo doses vary by animal model
  • Administration route in research: intratumoral injection or systemic injection in animal models
  • No clinical trials have been conducted in humans
  • This peptide is strictly a research compound and should not be self-administered
  • Consult an oncologist for any cancer-related treatment decisions
Peptide calculator: get your dose in syringe units →

Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.

PNC-27 Side Effects & Safety

Known Side Effects

  • No human safety data available — all evidence is preclinical, and the FDA has found bacterial contamination in PNC-27 products sold to consumers
  • Potential for immune activation against dying cancer cells (theoretical benefit but could cause inflammation)
  • Injection site reactions in animal studies
  • Unknown systemic toxicity profile in humans
  • Potential for off-target effects if normal cells transiently express surface HDM-2 under stress conditions

Safety Profile

PNC-27 is a preclinical research compound with no human safety data. Selectivity for cancer cells over normal cells has been reported in cell and animal studies, but the compound has not undergone the safety testing required for clinical use. In 2017 the FDA warned cancer patients not to use PNC-27 products sold online, after its laboratory found bacteria (Variovorax paradoxus, and later Ralstonia insidiosa) in samples of a PNC-27 solution; it said contaminated products can cause serious infections and that it has not approved PNC-27 for any disease. Key unknowns include pharmacokinetics in humans, potential immunogenicity, off-target effects on tissues that may transiently express surface HDM-2, and potential for tumor lysis syndrome with rapid cancer cell death. This compound should only be used in supervised research settings. It is not a substitute for established cancer therapies.

What to Expect

PNC-27 is a research compound not intended for self-administration. There is no clinical experience to describe a user timeline. In laboratory settings, cancer cell death occurs within 30–60 minutes of exposure at effective concentrations. In animal models, tumor regression has been observed over days to weeks with repeated administration. Any use of this compound should be within a supervised research or clinical context.

Common Stacks

Storage & Handling

Store lyophilized PNC-27 at -20°C or colder for long-term storage. Reconstitute with sterile PBS or bacteriostatic water. After reconstitution, store at 2–8°C and use within 1–2 weeks. PNC-27 is sensitive to degradation and should be handled with care. Protect from light, heat, and repeated freeze-thaw cycles. Aliquot into single-use portions when possible.

Pricing & Available Variants

$100price range
30mg

Prices sourced from peptides.gg marketplace. Prices may vary.

References

  1. Questions and Answers: FDA alerts companies to stop the illegal sale of products claiming to treat cancer. U.S. Food and Drug Administration. 2026.
  2. FDA warns cancer patients not to use PNC-27 products for treatment. U.S. Food and Drug Administration (archived page). 2017.
  3. Kanovsky M, Raffo A, Drew L, et al. Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells. Proc Natl Acad Sci U S A. 2001.
  4. Sarafraz-Yazdi E, Bowne WB, Adler V, et al. Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes. Proc Natl Acad Sci U S A. 2010.
  5. Sookraj KA, Bowne WB, Adler V, et al. The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide. Cancer Chemother Pharmacol. 2010.
  6. Sarafraz-Yazdi E, Mumin S, Cheung D, et al. PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis. Biomedicines. 2022.
  7. Davitt K, Babcock BD, Fenelus M, et al. The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells. Ann Clin Lab Sci. 2014.
  8. Wang H, Zhao D, Nguyen LX, et al. Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia. Leukemia. 2020.
  9. Michl J, Scharf B, Schmidt A, et al. PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo. Int J Cancer. 2006.
  10. Pincus MR, Silberstein M, Zohar N, et al. Poptosis or Peptide-Induced Transmembrane Pore Formation: A Novel Way to Kill Cancer Cells without Affecting Normal Cells. Biomedicines. 2024.

Related Peptides

Track PNC-27 in Your Protocol

Log your PNC-27 doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.

Start Tracking Free